Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Alan Borne

Internal Medicine Shreveport, LA Medical Doctor

NPI 1700881299 CMS profile 838602

1811 E Bert Kouns Industrial Loop, Suite 440, Shreveport, LA 71105

Open in the dashboard

General payments

$1,919

114 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Alan Borne of Shreveport, LA is reported in the CMS Open Payments database as having received $1,919 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $495 31
2020 General $479 31
2019 General $945 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Borne
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Alan Borne were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Alan Borne Internal Medicine median Middle half National median
2019 $945 $159 $48–$570 $163
2020 $479 $119 $33–$402 $114
2021 $495 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Novo Nordisk Inc $448 27 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $282 20 payments
  3. Astellas Pharma US Inc $173 4 payments
  4. Kowa Pharmaceuticals America, Inc. $136 7 payments
  5. Merck Sharp & Dohme Corporation $132 9 payments
  6. Pfizer Inc. $108 7 payments
  7. AstraZeneca Pharmaceuticals LP $84 6 payments
  8. Novartis Pharmaceuticals Corporation $61 4 payments
  9. Janssen Pharmaceuticals, Inc $57 3 payments
  10. Avanir Pharmaceuticals, Inc. $53 4 payments
  11. Other $383 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $1,733 110 payments
  2. Education $186 4 payments
Products named General payments · program years 2019–2021
  1. Tresiba $230 13 payments
  2. Ozempic $218 14 payments
  3. RYBELSUS $204 13 payments
  4. JARDIANCE $190 14 payments
  5. Livalo $136 7 payments
  6. JANUVIA $109 7 payments
  7. BELSOMRA $105 7 payments
  8. Bystolic $95 5 payments
  9. SPIRIVA RESPIMAT $92 6 payments
  10. ELIQUIS $74 5 payments
  11. Other $1,049 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record